Bei Akademie registrieren
Bristol Myers Squibb, US1101221083

Bristol Myers Squibb licenses oncology data: what it means for Bristol Myers Squibb stock

Published on 10/24/2026 at 10:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock costs EUR 55.35 in weekend trading on October 24, 2026. BMS will license Tempus data through 2031.

Upcoming dates and data

  • On October 23, 2026, Bristol Myers Squibb reported oncology data showing a 59 percent reduction in risk.
  • Bristol Myers Squibb stock trades in weekend trading at Lang & Schwarz at EUR 55.35 at 10:45 a.m. CEST on October 24, 2026.
  • The next Xetra session is scheduled for October 26, 2026.
  • Bristol Myers Squibb's third-quarter 2026 results conference call is scheduled for October 29, 2026.
Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.
Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb will license multimodal oncology data from Tempus through 2031 under a multi-year agreement announced on October 23, 2026. The agreement also gives Bristol Myers Squibb access to Tempus' Lens Platform for oncology drug development, according to Tempus.

Market context: Market report S&P 500.

The week in figures

At 10:45 a.m. CEST on October 24, 2026, Bristol Myers Squibb traded in weekend trading at Lang & Schwarz at EUR 55.35, with a bid of EUR 55.24 and an ask of EUR 55.46. The Xetra market was closed for the weekend session. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.

Chronology of the week

On October 23, 2026, Bristol Myers Squibb's investor-relations page listed interim oncology data for izalontamab brengitecan, reporting a 59 percent reduction in the risk of disease progression or death versus chemotherapy in the Phase 3 PANKU-Breast01 study. The issuer also listed a presentation of new oncology portfolio and pipeline data at the European Society for Medical Oncology congress. These items are listed on Bristol Myers Squibb's investor-relations page.

Dates of the coming week

The next Xetra session is scheduled for October 26, 2026. Bristol Myers Squibb's investor-relations calendar lists its third-quarter 2026 results conference call for October 29, 2026, according to the company.

Disclaimer...
en | US1101221083 | BRISTOL MYERS SQUIBB | boerse | 70403839 | bgmi